348640-07-3

Basic information

• Product Name: 4-BROMO-1-[(4-METHYLPHENYL)SULFONYL]-1H-PYRROLO[2,3-B]PYRIDINE
• Synonyms: 4-BROMO-1-[(4-METHYLPHENYL)SULFONYL]-1H-PYRROLO[2,3-B]PYRIDINE;1H-Pyrrolo[2,3-b]pyridine, 4-bromo-1-[(4-methylphenyl)sulfonyl]-;N-Tosyl-4-bromo-7-azaindole;4-Bormo-1-tosyl-7-azaindole;4-Bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine;4-Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridine;4-Bromo-1-tosyl-7-azaindo...;4-BroMo-1-tosyl-7-azaindole
• CAS NO: 348640-07-3
• Molecular Formula: C₁₄H₁₁BrN₂O₂S
• Molecular Weight: 351.22
• Product Categories: Heterocycle-Pyridine series
• Mol File: 348640-07-3.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 514.9 °C at 760 mmHg
• Flash Point: 265.2 °C
• Appearance: /
• Density: 1.59 g/cm³
• Vapor Pressure: 1.04E-10mmHg at 25°C
• Refractive Index: 1.684
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.14±0.30(Predicted)
• CAS DataBase Reference: 4-BROMO-1-[(4-METHYLPHENYL)SULFONYL]-1H-PYRROLO[2,3-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-1-[(4-METHYLPHENYL)SULFONYL]-1H-PYRROLO[2,3-B]PYRIDINE(348640-07-3)
• EPA Substance Registry System: 4-BROMO-1-[(4-METHYLPHENYL)SULFONYL]-1H-PYRROLO[2,3-B]PYRIDINE(348640-07-3)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 348640-07-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine is a chemical compound that can be classified as an organobromine compound, as it contains a bromine atom. It also falls under the class of organosulfur compounds due to the presence of a sulfur atom. The molecule is made up of a pyrrolopyridine backbone, which is a type of a heterocyclic organic compound. Additionally, it also has a sulfone group, characterized by a sulfur atom bonded to two oxygen atoms, connected to a part of the molecule identified as 4-methylphenyl. This chemical has applications in various fields including pharmaceuticals, research, and chemical synthesis. However, detailed information about its properties such as its stability, toxicity, and potential risks to health and environment requires further study.

InChI:InChI=1/C14H11BrN2O2S/c1-10-2-4-11(5-3-10)20(18,19)17-9-7-12-13(15)6-8-16-14(12)17/h2-9H,1H3

Upstream product

• 271-63-6 7-Azaindole 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 98-59-9 p-toluenesulfonyl chloride 
• 348640-06-2 4-bromo-7-azaindole 

Downstream Products

• 480423-17-4 4-bromo-2-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 916176-50-6 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1352232-88-2 (3R)-3-methyl-4-(6-(1-(S-methylsulfonimidoyl)cyclopropyl)-2-(1-tosyl-1H-pyrrolo[2,3-b]pyridine-4-yl)pyrimidin-4-yl)morpholine 
• 1352227-13-4 (R)-3-methyl-4-(6-((R)-S-methylsulfonimidoylmethyl)-2-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)morpholine 
• 1352226-88-0 4-[4-[1-[[S(R)]-S-methylsulfonimidoyl]cyclopropyl]-6-[(3R)-3-methyl-4-morpholinyl]-2-pyrimidinyl]-1H-pyrrolo[2,3-b]pyridine 
• 1352226-87-9 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((S)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b]pyridine 
• 1352232-89-3 (3R)-3-methyl-4-(6-(1-((R)-S-methylsulfonimidoyl)cyclopropyl)-2-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)morpholine 
• 1415928-58-3 4-bromo-2-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1014613-64-9 4-bromo-2-methyl-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

General methods for the synthesis and late-stage diversification of 2,4-substituted 7-azaindoles

As part of a medicinal chemistry program, we adapted known synthetic methods for the late-stage diversification of 2,4-substituted 7-azaindoles. The strengths and weaknesses of these strategies are discussed. In the course of this work, three optimized co

CDK9 Kinase inhibitors

The present application relates to CDK9 kinase inhibitors which provide a compound of formula (I) or a stereoisomer thereof. A solvate, a metabolite, a pharmaceutically acceptable salt or prodrug, and a pharmaceutical composition comprising the same. Also provided are the use of compounds and pharmaceutical compositions in the manufacture of a medicament for the treatment of cancer.

Synthesis of Differentially Protected Azatryptophan Analogs via Pd2(dba)3/XPhos Catalyzed Negishi Coupling of N-Ts Azaindole Halides with Zinc Derivative from Fmoc-Protected tert-Butyl (R)-2-Amino-3-iodopropanoate

Unnatural amino acids play an important role in peptide based drug discovery. Herein, we report a class of differentially protected azatryptophan derivatives synthesized from N-tosyl-3-haloazaindoles 1 and Fmoc-protected tert-butyl iodoalanine 2 via a Neg